TY - JOUR
T1 - Adiponectin as a predictor of mortality and readmission in patients with community-acquired pneumonia
T2 - a prospective cohort study
AU - Dungu, Arnold Matovu
AU - Ryrsø, Camilla Koch
AU - Hegelund, Maria Hein
AU - Sejdic, Adin
AU - Jensen, Andreas Vestergaard
AU - Kristensen, Peter Lommer
AU - Krogh-Madsen, Rikke
AU - Faurholt-Jepsen, Daniel
AU - Lindegaard, Birgitte
N1 - Copyright © 2024 Dungu, Ryrsø, Hegelund, Sejdic, Jensen, Kristensen, Krogh-Madsen, Faurholt-Jepsen and Lindegaard.
PY - 2024
Y1 - 2024
N2 - BACKGROUND: Adiponectin is secreted by adipocytes and is inversely associated with obesity. Given the association between low body mass index (BMI) and higher mortality risk after community-acquired pneumonia (CAP), we hypothesized that high adiponectin levels are associated with a higher risk of adverse clinical outcomes in patients with CAP.METHODS: In a prospective cohort study of 502 patients hospitalized with CAP, adiponectin was measured in serum at admission. The associations between adiponectin and clinical outcomes were estimated with logistic regression analyses adjusted for age, sex, and measures of obesity (BMI, waist circumference or body fat percentage).RESULTS: Adiponectin was associated with higher 90-day mortality for each 1 μg/mL increase [OR 1.02, 95% CI (1.00, 1.04), p = 0.048] independent of age and sex. Likewise, adiponectin was associated with a higher risk of 90-day readmission for each 1 μg/mL increase [OR 1.02, 95% CI (1.01, 1.04), p = 0.007] independent of age and sex. The association between adiponectin and 90-day mortality disappeared, while the association with 90-day readmission remained after adjusting for adiposity.CONCLUSION: Adiponectin was positively associated with mortality and readmission. The association with mortality depended on low body fat, whereas the association with readmission risk was independent of obesity.
AB - BACKGROUND: Adiponectin is secreted by adipocytes and is inversely associated with obesity. Given the association between low body mass index (BMI) and higher mortality risk after community-acquired pneumonia (CAP), we hypothesized that high adiponectin levels are associated with a higher risk of adverse clinical outcomes in patients with CAP.METHODS: In a prospective cohort study of 502 patients hospitalized with CAP, adiponectin was measured in serum at admission. The associations between adiponectin and clinical outcomes were estimated with logistic regression analyses adjusted for age, sex, and measures of obesity (BMI, waist circumference or body fat percentage).RESULTS: Adiponectin was associated with higher 90-day mortality for each 1 μg/mL increase [OR 1.02, 95% CI (1.00, 1.04), p = 0.048] independent of age and sex. Likewise, adiponectin was associated with a higher risk of 90-day readmission for each 1 μg/mL increase [OR 1.02, 95% CI (1.01, 1.04), p = 0.007] independent of age and sex. The association between adiponectin and 90-day mortality disappeared, while the association with 90-day readmission remained after adjusting for adiposity.CONCLUSION: Adiponectin was positively associated with mortality and readmission. The association with mortality depended on low body fat, whereas the association with readmission risk was independent of obesity.
UR - http://www.scopus.com/inward/record.url?scp=85190366577&partnerID=8YFLogxK
U2 - 10.3389/fmed.2024.1329417
DO - 10.3389/fmed.2024.1329417
M3 - Journal article
C2 - 38633314
SN - 2296-858X
VL - 11
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 1329417
ER -